Abstract Library

#4574 Long-acting somatostatin analogue injections for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and acromegaly: BackSOM – A patient preference study

Introduction: Long-acting somatostatin analogues, lanreotide and octreotide, are indicated for first-line treatment of GEP-NETs and acromegaly. Lanreotide was approved in 2007 in Europe, and is supplied as a prefilled, ready-to-use syringe (LAN-PF). In 2021, a generic form of lanreotide was released and supplied in a syringe requiring assembly (LAN-RA). To ensure patient compliance with treatment, it is important to understand their injection experiences.

Conference:

Presenting Author: Hernando Cubero J

Authors: Rodien-Louw C, Simo-Servat A, Dubois M, Sheppard J, McDonnell M,

Keywords: gastroenteropancreatic neuroendocrine tumour, GEP-NET, acromegaly, lanreotide, LA-SSA, somatostatin, patient preference,

#3510 Efficacy of 177- Lutetium DOTATATE Peptide Receptor Radionuclide Therapy in patients with metastatic NENs and carcinoid syndrome refractory to somatostatin analogues

Introduction: Optimal management of refractory carcinoid syndrome (RCS) represents an unmet clinical need in patients with metastatic Neuro Endocrine Neoplasms (NEN).

Conference:

Presenting Author: Ratnayake G

Authors: Ratnayake G, Koffas A, Theocharopoulos I, Hayes A, Navalkissoor S,

Keywords: carcinoid syndrome, PRRT,

#3453 Comparison of Lanreotide and Octreotide LAR use and outcomes for gastrointestinal neuroendocrine tumors in British Columbia, Canada

Introduction: The long-acting somatostatin analogues (LA-SSAs) octreotide LAR (OCT) and lanreotide (LAN) improve progression-free survival in neuroendocrine tumors (NETs), however no head-to-head comparison exists. We compared treatment patterns and efficacy in a population-based cohort from British Columbia, Canada.

Conference:

Presenting Author: Paul A

Authors: Paul A, Mendis S, Jao J, Boutin M, Safro M,

Keywords: lanreotide, octreotide LAR, neuroendocrine tumor, overall survival,

#2969 Lanreotide Autogel and Octreotide LAR Treatment Patterns: Results from a Nationwide French Retrospective Study

Introduction: Lanreotide autogel (LAN) and octreotide LAR (OCT) are long acting somatostatin analogues (LA-SSAs) used to treat acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Previous studies conducted in North America and Sweden showed some differences between both LA-SSAs in terms of dose and persistence.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Fagnani F, Feuilly M, Marteau F, de Zélicourt M, Kamenicky P,

Keywords: somatostatin analogues, treatment patterns, resource use,

#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis

Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Feuilly M

Authors: Feuilly M, Cristeau O, Clay E, François C, Whalen J,

Keywords: somatostatin analogues, economics,